| 000 | a | ||
|---|---|---|---|
| 999 |
_c16279 _d16279 |
||
| 003 | OSt | ||
| 005 | 20220208153330.0 | ||
| 008 | 220208b xxu||||| |||| 00| 0 eng d | ||
| 040 |
_aAIKTC-KRRC _cAIKTC-KRRC |
||
| 100 |
_915955 _aGhasemian, Elham |
||
| 245 | _aAnalytical method validation, pharmacokinetics and bioequivalence study of dimethyl fumarate in healthy iranian volunteers | ||
| 250 | _aVol.13(9) | ||
| 260 |
_aM P _bInnovare Academic Sciences Pvt Ltd _c2021 |
||
| 300 | _a6-10p. | ||
| 520 | _aObjective: Pharmacokinetic evaluation of Dimethyl Fumarate (DMF) in the Iranian population wasn’t studied. So, the aim of this research is the validation of the analytical method and evaluation of the pharmacokinetic properties and bioequivalence of the generic form of this drug versus the reference product.Methods: 2 single-dose, test, and reference DMF products were orally administered to 24 healthy volunteers. The washout period was 28 dbetween the treatments. Monomethyl fumarate as the metabolite of DMF was analyzed by liquid chromatography-tandem mass spectrometry (LC-MS/MS) and the method was validated. Also, the pharmacokinetic parameters were calculated for bioequivalence evaluation. Results: The analytical method was validated and linear over the range of 31.25-4000 ng/ml (R2Conclusion: The applied analytical method is selective, accurate, precise, and repeatable for the analysis of monomethyl fumarate (MMF) in plasma. Also, the bioequivalence study showedno significant difference between the pharmacokinetic parameters of these 2 products. So, the DMF test product can be claimed to be bioequivalent with the reference product | ||
| 650 | 0 |
_94639 _aPHARMACEUTICS |
|
| 700 |
_915957 _aSadrai, Sima |
||
| 773 | 0 |
_tInternational journal of pharmacy and pharmaceutical science _x2656-0097 _dBhopal Innovare Academic Sciences Pvt Ltd |
|
| 856 |
_uhttps://innovareacademics.in/journals/index.php/ijpps/article/view/42328/25272 _yClick here |
||
| 942 |
_2ddc _cAR |
||